Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agarwala, S. S.
Right arrow Articles by Kirkwood, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agarwala, S. S.
Right arrow Articles by Kirkwood, J. M.

Annals of Surgical Oncology, Vol 2, Issue 4 365-371, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Potential uses of interferon alpha 2 as adjuvant therapy in cancer

S. S. Agarwala and J. M. Kirkwood
Division of Medical Oncology, University of Pittsburgh, PA 15213-2582, USA.

BACKGROUND: The purpose of this study was to provide an overview of the potential uses of adjuvant interferon (IFN) therapy for resected solid tumors at high risk for postsurgical relapse. METHODS: A MEDLINE search (1970-1994) of the English-language literature for original articles, reviews, and abstracts addressing IFN use in the adjuvant setting together with the authors' collective experience formed the basis for this review. RESULTS: The use of adjuvant IFN-alpha has been studied most extensively in conjunction with the treatment of melanoma. Fewer data are available on IFN-alpha use for the treatment of other solid tumors. In melanoma, there is evidence from Intergroup trials (Eastern Cooperative Oncology Group and World Health Organization) that IFN-alpha 2a given for 1-3 years prolongs the interval to relapse and may have a survival benefit. Trials of adjuvant IFN, with and without chemotherapy, are ongoing in the treatment of renal cell carcinoma and colorectal adenocarcinoma. Its value in the treatment of osteosarcoma and high-grade astrocytoma is unknown. CONCLUSIONS: The use of IFN in the adjuvant setting is an exciting area of medical and surgical oncology and has the potential to prolong the time to relapse and to increase survival of patients with melanoma. Its role in the adjuvant therapy of other solid tumors remains to be defined.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
F. Palamara, S. Meindl, M. Holcmann, P. Luhrs, G. Stingl, and M. Sibilia
Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod
J. Immunol., September 1, 2004; 173(5): 3051 - 3061.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. B. Lesinski, B. Badgwell, J. Zimmerer, T. Crespin, Y. Hu, G. Abood, and W. E. Carson III
IL-12 Pretreatments Enhance IFN-{alpha}-Induced Janus Kinase-STAT Signaling and Potentiate the Antitumor Effects of IFN-{alpha} in a Murine Model of Malignant Melanoma
J. Immunol., June 15, 2004; 172(12): 7368 - 7376.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.